
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
19 December 2023
Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds
83-year-old actor Richard Tate will appear on screens from 26th December onwards to support Leukaemia UK’s call for legacy pledges (otherwise known as gifts in Wills), after surviving leukaemia thanks…
26 October 2021
Leukaemia UK announced as one of five charities for star-studded event Shall We Dance? with Dame Arlene Phillips and Anton Du Beke
Leukaemia UK is delighted to have been announced as one of five charities for whom the proceeds of a new star-studded dance event, Shall We Dance?, will go towards when it takes place next year.
15 June 2018
Nick Boles’ Ambulatory Care Unit opening speech
An edited extract of the speech Nick Boles MP made at the official opening of the Leukaemia UK Ambulatory Care Unit.
11 February 2026
The National Cancer Plan: what does it mean for people with leukaemia?
The Government’s new National Cancer Plan for England, which launched on World Cancer Day 2026, marks the most significant progress in policy for leukaemia and other blood cancers in more…